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1684as more abnormal LV geometry
and presence of LV myocardial
dysfunction (9,10).
Epidemiologic data have dem-
onstrated that obesity is associ-
ated with increased CVmorbidity
and total mortality both in men
and women (3,11). In contrast,
among patients with coronary
artery disease, several studies have
reported that overweight and obe-
sity are associated with better
outcome after coronary revascu-
larization therapy (12,13). This
phenomenon has been called the
obesity paradox. Recently, Rob-
erts et al. (14) reported bettersurvival in mildly obese patients also after surgical aortic valve
replacement for AS on the basis of registry data. However,
whether increased BMI independently inﬂuences CV
morbidity and mortality in AS has not been reported from
a prospective, longitudinal study. Thus, the aim of the present
study was to determine the impact of increased BMI on rate of
major CV events in initially asymptomatic, mild to moderate
AS patients participating in the SEAS study.Methods
Study population. The present analysis was a prospectively
planned explorative substudy performed within the 1,873
women andmen45 to85 years of agewith asymptomatic,mild-
to-moderate AS with peak aortic jet velocity between 2.5 and
4.0 m/s, randomized in the SEAS study to >4 years of lipid-
lowering treatment with simvastatin 40 mg and ezetimibe
10 mg daily in combination (15). Exclusion criteria in the
SEAS study were known CV disease, diabetes mellitus, or any
condition requiring lipid-lowering therapy. For the present
analysis, 1,664 patients with registered body stature and
complete study echocardiogram at baseline and at least 1
follow-up study visit before occurrence of any CV endpoint
were included. The last study echocardiogram was deﬁned as
the ﬁnal study echocardiogram in patients who did not expe-
rience CV events and the last echocardiogram taken before
a CV event in those who did.We used the modiﬁed American
Heart Association/National Heart, Lung, and Blood Institute
criteria to identify presence of MetS (16). Because waist
circumference was not measured in the SEAS study, BMI
was used as a substitute for the deﬁnition of obesity (17,18).
The MetS was considered present if at least 3 of the following
5 criteria at baseline were fulﬁlled: 1) BMI 30 kg/m2;
2) blood pressure 130/85 mm Hg; 3) fasting serum
glucose 100 mg/dl 4) serum triglycerides 1.7 mmol/l; and
5) serum high-density lipoprotein cholesterol<1.3 mmol/l in
women and <1.03 mmol/l in men.
Endpoints. The pre-speciﬁed primary endpoint in the
SEAS study was major CV events, a composite endpointincluding AS-related events (combined aortic valve replace-
ment, congestive heart failure due to progression of AS, and
CV death) and ischemic CV events (combined nonfatal
myocardial infarction, hospital stay for unstable angina,
coronary artery bypass grafting [CABG], percutaneous coro-
nary intervention [PCI], CV death, and non-hemorrhagic
stroke) (19). This analysis focused on the pre-speciﬁed
secondary outcomes AS-related events and ischemic CV
events analyzed separately and on total mortality, a predeﬁned
tertiary study endpoint. This analysis also assessed the
post hoc deﬁned endpoint of combined hospital stay for
heart failure and death from any cause. All outcomes were
classiﬁed by an independent endpoint classiﬁcation com-
mittee whose members did not have access to the study-
group assignments (19).
Echocardiography. Echocardiography was performed in
173 study centers in Europe at baseline, annually during
follow-up, and before planned aortic valve replacement,
according to a standardized echocardiographic protocol and
sent for blinded interpretation at the Echocardiography Core
Laboratory at Haukeland University Hospital in Bergen,
Norway (15,20). All echocardiograms were initially read by
a junior and ﬁnally by a senior investigator (93% of baseline
and 100% of follow-up echocardiograms were ﬁnally read by
the same senior investigator) at off-line digital workstations
with Image Arena (TomTec Imaging Systems GmbH,
Unterschleissheim, Germany) software (21). Quantitative
echocardiography was performed following the joint Euro-
pean Association of Echocardiography and the American
Society of Echocardiography guidelines (22). The LV mass
was indexed for height in the allometric power of 2.7 (23).
Abnormal LV geometry was considered present when relative
wall thickness 0.43 or if LV mass/height2.7 exceeded the
prognostically validated cutoff values 46.7 g/m2.7 in women
and 49.2 g/m2.7 in men (24). The LV systolic function was
assessed by Teichholz’ ejection fraction and stress-corrected
midwall shortening calculated as the ratio of actual to pre-
dicted midwall shortening for the actual circumferential end-
systolic stress, taking mean aortic gradient into account
(25–27). Evaluation of AS severity was performed according
to the joint European Association of Echocardiography and
American Society of Echocardiography guidelines (28).
Aortic and mitral valve regurgitation were graded by color
Doppler (29,30).
Statistical analysis. The IBM SPSS 20.0 software (IBM
Corporation, Armonk, New York) was used for data
management and analysis. Data are presented as mean  SD
for continuous variables and as percentages for categorical
variables. The number of antihypertensive drugs was not nor-
mally distributed and therefore reported as median and range.
The study populationwas divided into 3BMI classes according
to clinical guidelines: normal weight, overweight, and obese
(BMI 18.5 to 24.9 kg/m2, 25.0 to 29.9 kg/m2, and30 kg/m2,
respectively) (31). Nineteen patients with BMI <18.5 kg/m2
were excluded from the study population for statistical reasons
due to the small subgroup size. Comparisons between groups
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1685were done with analysis of variance (ANOVA), general linear
models, ANOVA for repeated measures with post hoc
tests, and Bonferroni adjustment for multiple comparisons
and Kruskal-Wallis ANOVA as appropriate. Univariate
correlations were tested with Pearson’s correlation coefﬁcient.
Kaplan-Meier curves were used to calculate the cumulative
proportions of CV events over 4.3 years and reported as
percentage  SEM. The impact of BMI on different types of
events was assessed with multiple Cox regression analyses
adjusting for sex, mean aortic gradient, smoking, hypertension,
abnormal LV geometry, LVEF, and randomized study treat-
ment in the ﬁrst model and adding age to the covariates in the
second model. The models assessing total mortality and
combined hospital stay for heart failure and death from any
cause were also adjusted for any intervening nonfatal events
included in the primary study endpoint. Two-tailed p < 0.05
was considered signiﬁcant both in univariate and multivariate
analyses.
Results
Patients. Cardiometabolic risk factors including sex, age,
smoking, hypertension, fasting serum glucose, and lipids
differed signiﬁcantly between BMI classes (Table 1). The
prevalence of hypertension increased in parallel with BMI
class, as did fasting serum glucose and serum triglycerides,
whereas total serum cholesterol and high-density lipoproteinTable 1
Baseline Clinical Characteristics of Normal
Weight, Overweight, and Obese Groups of Patients
Normal Weight
(n ¼ 593)
Overweight
(n ¼ 737)
Obese
(n ¼ 334)
Women (%) 44.2 29.2* 48.5*
Age (yrs) 69  9.7 66  9.9* 67  8.8
BMI (kg/m2) 23  1.5 27  1.4 33  3.4
Height (m) 1.7  0.1 1.7  0.1y 1.7  0.1y
Weight (kg) 66.5  8.5 80.4  9.3* 94.6  12.7*
Hypertension (%) 82.8 85.2* 95.2*
Systolic blood pressure
(mm Hg)
144  21 144  20 147  18y
Diastolic blood
pressure (mm Hg)
80  10 82  10* 84  10*
Smoking (%) 22.8 18.5* 12.3*
Number of
antihypertensive
agents
1.7  1.0 1.8  1.0 2.0  1.1*
Glucose (mg/dl) 92.2  11.0 95.2  14.4* 101.4  18.9*
Total cholesterol
(mmol/l)
5.8  1.0 5.7  1.0 5.6  1.0y
HDL cholesterol
(mmol/l)
1.7  0.4 1.4  0.4* 1.3  0.4*
LDL cholesterol
(mmol/l)
3.6  0.9 3.6  0.9 3.5  0.9
LDL/HDL cholesterol
ratio
2.4  0.9 2.7  1.0* 2.7  0.9*
Triglycerides (mmol/l) 1.2  0.5 1.5  0.7* 1.7  0.8*
Metabolic
syndrome (%)
9.9 20.7* 71.2*
Values are % or mean  SD. *p < 0.001 vs. normal group. yp < 0.05 vs. normal group.
BMI ¼ body mass index; HDL ¼ high-density lipoprotein; LDL ¼ low-density lipoprotein.cholesterol fell progressively. The MetS was identiﬁed in
421 (27.3%) patients; the incidence increased exponentially
with BMI class (p < 0.001) (Table 1).
Change in left ventricular structure during follow-up.
The time span between the baseline and the last study
echocardiogram did not differ between normal weight
(3.4  1.4 years), overweight (3.4  1.4 years), and obese
groups of patients (3.4  1.3 years, p ¼ 0.706). The LV
mass and prevalence of abnormal LV geometry increased in
parallel with BMI class (Fig. 1, Table 2). Obesity was
associated with higher prevalence of abnormal LV geometry
throughout the study (Fig. 1). The LVEF remained normal
(above 50%) in 97.2% of patients during progression of AS.
Stress-corrected midwall fractional shortening was progres-
sively reduced during follow-up in all BMI classes and was
signiﬁcantly lower in obese patients compared with the
normal weight group throughout the study (Fig. 2).
Outcome. The progression of AS did not differ between
BMI groups (0.19  0.24 m/s/year in the normal weight
group vs. 0.21  0.34 m/s/year in the overweight group vs.
0.19  0.30 m/s/year in obese patients, p ¼ 0.547) or in
relation to presence of MetS (0.19  0.23 m/s/year in
patients without MetS vs. 0.22  0.43 m/s/year in patients
with MetS, p ¼ 0.211).
Within the 459 patients who underwent aortic valve
replacement, the AS severity assessed from peak aortic jet
velocity, mean aortic gradient, and aortic valve area did notFigure 1
Prevalence of Abnormal Left Ventricular Geometry
in Groups of Patients
Compared with normal weight patients, overweight and obese patients
had signiﬁcantly higher prevalence of abnormal left ventricular geometry
during follow-up.
Table 2 Echocardiographic Characteristics of Patients at Baseline and at Last Visit
Baseline Last Visit
Normal Weight
(n ¼ 593)
Overweight
(n ¼ 737)
Obese
(n ¼ 334)
Normal Weight
(n ¼ 593)
Overweight
(n ¼ 737)
Obese
(n ¼ 334)
Left atrial diameter (cm) 3.5  0.6 3.8  0.6* 4.1  0.6* 3.6  0.6 3.8  0.7* 4.0  0.7*
LV end-diastolic diameter (cm) 4.9  0.6 5.1  0.6* 5.2  0.6* 4.6  0.6 4.8  0.7* 4.9  0.7*
Septum end-diastolic diameter (cm) 1.1  0.3 1.2  0.3* 1.2  0.3* 1.3  0.3 1.4  0.3* 1.5  0.3*
Posterior wall end-diastolic diameter (cm) 0.8  0.2 0.9  0.2* 0.9  0.2* 1.0  0.2 1.1  0.2* 1.1  0.2*
LV mass (g) 171  55 202  66* 220  79* 205  63 233  72* 254  91*
LV mass/height2.7 (g/m2.7) 40.6  12.0 46.7  14.0* 53.6  17.2* 48.8  13.8 53.8  15.4* 61.8  18.7*
Relative wall thickness 0.35  0.09 0.36  0.09 0.37  0.09 0.47  0.11 0.47  0.12 0.47  0.11
Stress-corrected midwall shortening (%) 102  20 99  20* 97  19* 78  17 79  17 77  15y
Ejection fraction (%) 67  8.0 65  8.3* 65  8.1* 65  8.7 65  8.4 64  8.4
Aortic valve area (cm2) 1.2  0.4 1.3  0.5* 1.3  0.5y 1.1  0.4 1.2  0.5* 1.2  0.5*
Aortic valve area/body surface area (cm2/m2) 0.67  0.22 0.69  0.24 0.64  0.22 0.60  0.23 0.62  0.23 0.59  0.22
Peak aortic jet velocity (m/s) 3.1  0.5 3.1  0.5 3.1  0.6 3.7  0.8 3.7  0.8 3.6  0.8
Mean aortic gradient (mm Hg) 23  9 22  9 23  9 35  15 33  15 33  14
Values are mean  SD. *p < 0.01 vs. normal weight group. yp < 0.05 vs. normal weight group.
LV¼ left ventricular.
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1686differ between normal weight, overweight, and obese groups
of patients at the pre-operative echocardiogram. Compared
with the normal weight group, overweight patients had
lower cumulative proportions of ischemic CV events and
AS-related events, whereas the cumulative proportions of
these events did not differ between obese and normal weight
groups (Table 3). In univariate Cox regression, overweight
was associated with a 17% to 22% lower rate of AS-related
(p ¼ 0.04) and ischemic CV events (p ¼ 0.05) (Table 4).Figure 2
Stress-Corrected Midwall Shortening in
Groups of Patients
Compared with normal weight patients, stress-corrected midwall shortening was
signiﬁcantly lower in obese patients throughout the study.In the ﬁrst multiple Cox regression model, adjusting for sex,
smoking, hypertension, LV geometry, LVEF, mean aortic
gradient, and randomized study drug treatment, overweight
was associated with lower rates of ischemic CV events
(hazard ratio: 0.69, 95% conﬁdence interval: 0.53 to 0.90,
p ¼ 0.007) and AS-related events (hazard ratio: 0.82, 95%
conﬁdence interval: 0.68 to 0.99, p ¼ 0.04), compared with
the normal weight group, whereas obesity did not signiﬁ-
cantly inﬂuence rates of these events. Higher BMI class was
not associated with statistically signiﬁcant increased CV or
total mortality or combined hospital stay for heart failure and
death from any cause in this model.
However, overweight patients were on average 2 years
younger than normal weight patients at the time of an
ischemic CV event (71  10 years vs. 73  10 years, p <
0.01). When age was added to the covariates in a second
Cox regression model, the association between overweight
and lower rates of AS-related and ischemic CV events
became statistically nonsigniﬁcant (Table 5). Furthermore,
in this second model, overweight and obesity was associated
with a 46% to 67% higher rate of death from any cause and
a 42% to 69% higher rate of combined hospital stay for heart
failure and death from any cause (Table 5). When BMI class
was replaced by an indicator variable for presence of MetS in
this model, baseline MetS did not signiﬁcantly inﬂuence
rates of these CV events (data not showed).
Discussion
BMI and progression of AS. To our knowledge, this is the
ﬁrst large prospective study in patients with initially
asymptomatic, mild to moderate AS reporting the effect of
elevated BMI on outcome.
Although having elevated BMI was associated with
clustering of cardiometabolic risk factors also in the SEAS
population, the progression rate of AS did not differ
between BMI classes or in relation to presence of MetS.
Table 3
Cumulative Proportions of CV Events Over 4.3 Years
in Groups of Patients With Normal Weight,
Overweight, and Obesity
Normal
Weight
(n ¼ 593)
Overweight
(n ¼ 737)
Obese
(n ¼ 334)
Ischemic CV events (%) 19  2 15  1* 18  2
AS-related events (%) 34  2 29  2y 33  3
Coronary artery bypass
grafting (%)
11  1 8  1 8  2
Myocardial infarction (%) 2  1 2  1 3  1
CV deaths (%) 6  1 4  1 6  1
Total mortality (%) 9  1 10  1 12  2
Combined hospital stay for heart
failure and death from any
cause (%)
10  1 11  1 13  2
Values are cumulative percentage  SEM. *p ¼ 0.05. yp < 0.05, vs. normal weight group.
AS ¼ aortic valve stenosis, CV ¼ cardiovascular.
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1687This was a surprising ﬁnding, contrasting previous reports
(18). Ngo et al. (32) reported obesity and smoking as
independent predictors of a more rapid progression of AS
from a small study in 87 elderly patients with mild asymp-
tomatic AS who underwent 2 serial echocardiograms during
a 2.5-year period. Similarly Briand et al. (18) reported
a 2-fold increased progression rate of AS as well as a 36%
lower event-free survival rate over 3 years in 105 patients
with the MetS and at least moderate AS. From the
ASTRONOMER study, Capoulade et al. (9) reported that
MetS in asymptomatic AS predicted more rapid progression
of AS. The different ﬁndings in the SEAS study compared
with the ASTRONOMER study might be related to the
less sensitive measure of MetS used in the SEAS study but
also to important differences in CV risk proﬁle between
these 2 study populations, in particular the younger age,
higher prevalence of smoking, as well as the much lower
prevalence of concomitant hypertension in the ASTRON-
OMER study. Indeed a signiﬁcant age-MetS interaction
was also reported in that study, and more rapid AS pro-
gression was particularly found in MetS patients <57 years
of age. Compared with the study by Briand et al., the SEAS
study excluded patients with diabetes and hypercholester-
olemia and had lower prevalence of smokers. However, our
ﬁndings are in line with a report from the Multi-Ethnic
Study of Atherosclerosis, which demonstrated an associa-
tion between presence of the MetS and diabetes and
increased aortic valve calcium but not between MetS and the
rate of progression of AS as validated by CT (33).
BMI and outcome. Overweight and obesity were not as-
sociated with increased rate of ischemic CV or AS-related
events when adjusted for confounders including age in
multivariate analyses, regardless of the clustering of car-
diometabolic risk factors with higher weight. However,
increased BMI retained the association with a higher rate of
mortality and combined hospital stay for heart failure and
death from any cause compared with those with normal
weight. In contrast, the obesity paradox has been described
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1688in several publications from outcome studies in patients
undergoing coronary revascularization with PCI or CABG
(12,13,34). Oreopoulos et al. (12) found no evidence of
reduced event-free survival in patients with BMI >25 kg/m2
on short-term (within 30 days) and long-term (up to 5 years)
mortality after PCI and CABG. The Scottish Coronary
Revascularisation register, including 4,880 patients who
underwent elective ﬁrst time PCI, reported signiﬁcantly
lower risk of death during 5-year follow-up for overweight
compared with normal weight patients (13). Similar results
were found in a prospective Australian multicenter study of
4,762 patients undergoing PCI, reporting higher burden of
CV risk factors yet lower mortality and rate of major adverse
CV events among obese patients compared with their
normal weight counterparts (34). In contrast, Azimi et al.
(35) from the Western Denmark Heart Registry reported
a 35% increased risk for death in patients with BMI
>40 kg/m2 and established CV disease but superior survival
in overweight patients compared with their normal weight
counterparts.
Recently, Roberts et al. (14) reported a strong association
between BMI and post-operative survival in AS patients
undergoing surgical aortic valve replacement from registry
data. In particular, mildly obese patients (BMI in the low
30s) had superior survival rate compared with normal weight
and morbidly obese groups of patients. These ﬁndings are
not conﬁrmed by the results from our large prospective
study. Patients with increased BMI experienced ischemic
CV events at a younger age than normal weight patients, as
also reported from Madala et al. (36). We cannot exclude
selection bias on the part of the physicians in the sense that
the most ﬁt of the patients among the overweight and obese
patients were referred for operation, but the same principle
can equally be expected to be applied in the group of the
normal weight patients. However, as demonstrated, AS
severity did not differ between normal weight, overweight,
and obese patient groups at the pre-operative echocardio-
gram. Age was a strong predictor of adverse events in our
population, and the signiﬁcant association between over-
weight and lower rate of ischemic CV and AS-related events
disappeared when age was taken into account in multivariate
analysis. However, increased BMI remained associated with
increased mortality and combined hospital stay for heart
failure and death from any cause in both univariate and
multivariate analysis.
BMI and LV geometry and function. Increased BMI
signiﬁcantly inﬂuenced LV mass and was associated with
more abnormal LV geometry throughout the study duration,
in line with previous ﬁndings in general and hypertensive
population (7–9). Obesity was associated with excessive LV
mass and reduced LV myocardial function, conﬁrming
results from studies in the general population and in AS
patients (37,38). Of note, in the present study, LVEF
remained normal in the vast majority of patients indepen-
dent of BMI class, whereas stress-corrected midwall short-
ening was persistently lower in obese patients.
JACC Vol. 62, No. 18, 2013 Rogge et al.
October 29, 2013:1683–90 Overweight and Obesity in Aortic Valve Stenosis
1689Clinical implications. The ﬁndings of the present
prospective analysis suggest that closer follow-up is not
indicated in overweight patients with mild-to-moderate AS.
In particular, overweight AS patients without hypercholes-
terolemia, diabetes mellitus, a history of CV disease, or renal
impairment have AS progression comparable to their
normal weight counterparts and are not in need of special
strategies or earlier valve intervention. Management of car-
diometabolic risk factors associated with higher BMI should
follow general recommendations for AS patients. Increased
BMI predisposes to heart failure and increased mortality in
AS, as in the general population. Weight normalization is
likely to improve prognosis in AS patients, but this effect was
not tested in the present study.
Study limitations. The SEAS study did not include
patients with CV disease, diabetes mellitus, known reduced
LVEF, renal impairment, or other major valvular heart
disease. Therefore the present results are not applicable to
these subpopulations. However, the elimination of impor-
tant confounders also allowed a more targeted analysis of the
prognostic effect of increased BMI in AS.
It is well known that BMI is a crude measurement of
obesity, inferior to waist circumference. Waist circumference
was not recorded in the SEAS study. We chose, to facilitate
comparison with previous publications in AS, a similar
approach as Briand et al. (18) for identiﬁcation of MetS by
substitutingwaist circumference withBMI30 kg/m2.Thus,
the difference between the modiﬁed National Cholesterol
Education ProgramdAdult Treatment Panel III criteria used
by Briand et al. and the deﬁnition ofMetS used in the present
study was merely the cutoff value for elevated fasting glucose,
which is 110 mg/dl in National Cholesterol Education
Program–Adult Treatment Panel III and 100 mg/dl in the
updated American Heart Association/National Heart, Lung,
and Blood Institute Scientiﬁc statement (16,39). In general,
comparison between studies using different criteria for MetS
should be done with caution.
This study does not address the prognostic implication of
underweight in AS, due to the exclusion of the very limited
number of patients that fell into that category.Conclusions
In patientswith initially asymptomaticAS,without knownCV
disease or diabetes mellitus, participating in the SEAS study,
overweight and obesity were not associated with increased AS
progression rate or rates of AS-related or ischemic CV events.
However, both overweight and obesity were associated with
increased total mortality as well as combined hospital stay for
heart failure and death from any cause.Reprint requests and correspondence: Dr. Barbara P. Rogge,
Department of Heart Disease, Haukeland University Hospital,
5021 Bergen, Norway. E-mail: barbara_lund@yahoo.no.REFERENCES
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